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Introduction: The PI3K/Akt/mammalian target of rapamycin path-
way is activated in a majority of malignant pleural mesotheliomas 
(MPM). We evaluated the activity of everolimus, an oral mammalian 
target of rapamycin inhibitor, in patients with unresectable MPM.
Methods: MPM patients who had received at least one but no more 
than two prior chemotherapy regimens, which must have been plati-
num-based, were treated with 10 mg of everolimus daily. The primary 
endpoint was 4-month progression-free survival (PFS) by RECIST 1.1.
Results: A total of 59 evaluable patients were included in the analy-
sis. The median duration of treatment was 2 cycles (56 days). Overall 
response rate was 2% [95% confidence interval (CI): 0–12%] by 
RECIST 1.1 and 0% (0–10%) by modified RECIST for MPM. The 
4-month PFS rate was 29% (95% CI: 17–41%) by RECIST 1.1, and 
27% (95% CI: 16–39%) by modified RECIST. The median PFS 
was 2.8 months (95% CI: 1.8–3.4) by RECIST 1.1. The median 
overall survival was 6.3 months (95% CI: 4.0–8.0). There was no 
difference in PFS among patients who received one or two prior che-
motherapy regimens (p = 0.74). There was no difference in overall 
survival between patients with epithelioid histology versus other 
types (p = 0.47). The most common toxicities were fatigue (59%), 
hypertriglyceridemia (44%), anemia (42%), oral mucositis (34%), 
nausea (32%), and anorexia (32%). The most common grade 3 to 4 
toxicities were fatigue (10.2%), anemia (6.8%), and lung infection 
(6.8%).
Conclusion: Everolimus has limited clinical activity in advanced 
MPM patients. Additional studies of single-agent everolimus in 
advanced MPM are not warranted.
Key Words: Malignant pleural mesothelioma, mTOR inhibitor, 
Everolimus, Modified RECIST.
(J Thorac Oncol. 2015;10: 387–391)
Multiple signaling pathways are activated in malignant pleural mesothelioma (MPM) including the PI3K-Akt-
mammalian target of rapamycin (mTOR) pathway. MPM cell 
lines1 and tumor samples2–4 frequently exhibit highly acti-
vated Akt, leading to phosphorylation of mTOR, 4EBP1, and 
FKHD, among others.3,4 Inhibition of the Akt pathway by the 
mTOR inhibitor rapamycin in MPM cells leads to G1 arrest,2 
overcomes acquired resistance to apoptosis in MPM,5 and 
inhibits cell migration on extracellular matrix.6 Sirolimus, 
another mTOR inhibitor, led to cell death of MPM cell lines 
alone and to a much greater extent in conjunction with cis-
platin.7 Furthermore, temsirolimus alone or in combination 
with cisplatin inhibited MPM cell growth both in vitro and in 
vivo xenograft models.8 Thus, mTOR inhibitors demonstrated 
compelling preclinical activity in MPM models.
Everolimus is an orally available inhibitor of mTOR 
that has been approved for use in renal cell carcinoma, 
pancreatic neuroendocrine tumors, angiomyolipoma in 
patients with tubular sclerosis complex, and in combination 
with exemestane in hormone receptor-positive breast can-
cer patients after progression on letrozole or anastrozole.9 
Here, we report the results of a phase II study investigating 
the clinical activity of single-agent everolimus in advanced 
MPM patients who have progressed after platinum-based 
chemotherapy.
PATIENTS AND METHODS
Inclusion Criteria
Eligible patients must be 18 years or older with histologi-
cally proven epithelioid, sarcomatoid, or biphasic unresectable 
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MPM, zubrod performance status of 0 to 1, adequate hema-
tologic function (absolute neutrophil count > 1500/ml and 
platelets > 100,000/ml), hepatic function (serum bilirubin < 
upper limit of normal and transaminases < 1.5 times upper 
limit of normal), and renal function (serum creatinine < 1.5 
times upper limit of normal or a measured creatinine clear-
ance > 50 ml/min).
Patients were required to have failed at least one prior 
platinum-based therapy but no more than two prior systemic 
therapeutic regimens (including biologics, targeted and 
immunotherapies). Pleural space washing with cisplatin was 
not considered systemic treatment. Neoadjuvant and/or adju-
vant systemic therapy was not considered as a prior regimen 
if more than 12 weeks had elapsed between treatment and 
disease progression. Patients may have received prior surgery 
(e.g., pleurectomy) provided that at least 28 days had elapsed 
and all toxicities surgery had resolved. Patients must not have 
had any prior mTOR inhibitor therapy or central nervous sys-
tem metastasis.
Patients were ineligible if they had severe systemic 
comorbid disease. Pregnant or breast-feeding patients were 
excluded. Patients who had prior pulmonary emboli could be 
on therapeutic low-molecular heparin. However, patients on 
coumadin anticoagulation must have had an international nor-
malized ratio of less than 1.5 within 28 days before registration 
to the trial. Patients must not be on chronic, systemic immuno-
suppressive treatment; however, a stable regimen of topical or 
inhaled corticosteroids or corticosteroids given at doses equiva-
lent to prednisone less than 20 mg/day and given for a minimum 
of 4 weeks were allowed before the first dose of everolimus.
The protocol and informed consent document were 
approved by the Cancer Therapy Evaluation Program of the 
National Cancer Institute and the institutional review boards 
of participating Southwest Oncology Group (SWOG) member 
sites. Written informed consent was obtained from all patients 
before enrollment.
Study Design and Protocol Treatment
The S0722 treatment protocol (ClinicalTrials.gov_iden-
tifier: NCT00770120) consisted of single-agent everolimus 
administered orally at 10 mg once daily until disease progres-
sion or unacceptable toxicity. Adverse events were graded 
according to the National Cancer Institute CTC Version 3.0. 
Patients who experienced more than grade 3 nonhemato-
logic and/or grade 4 hematologic toxicities were allowed two 
sequential dose modifications to 5 mg once daily and 5 mg 
once every other day. Treatment was held until all toxicities 
resolved to less than grade 1.
Patient history, physical examination, and laboratory 
analyses were performed within 28 days before cycle 1 and 
on day 1 of each subsequent treatment cycle. Radiographic 
tumor measurements were performed after every two treat-
ment cycles. Tumor responses were determined by RECIST 
1.1 and modified RECIST.10 Patients were withdrawn from the 
study due to disease progression, unacceptable toxicity, treat-
ment delay of more than 2 weeks for pneumonitis, treatment 
delay of more than 3 weeks for any other reason, or if more 
than 2 dose reductions were required.
Statistical Considerations and 
Statistical Analysis
The primary objective of this study was 4-month pro-
gression-free survival (PFS) rate using RECIST 1.1.11 It was 
assumed that if the true 4-month PFS is less than 30%, evero-
limus would not warrant further investigation, while if the 
true 4-month PFS is more than 50%, it will be of considerable 
interest. Using a two-stage design, initially 20 patients would 
be enrolled. If more than 5 of those 20 patients were alive and 
progression-free at 4 months, additional 35 patients would be 
enrolled. If 23 of 55 patients were alive and progression-free 
at 4 months, everolimus would be considered as having poten-
tial activity in MPM. This design had 91% power to detect an 
increase from a 4-month PFS of 30% to 4-month PFS of 50% 
using a one-sided significance test of 4%. Secondary objec-
tives included evaluating overall response rate (ORR) and 
overall survival (OS) using RECIST 1.1, and ORR and PFS 
using the modified RECIST for pleural tumors. PFS and OS 
estimates were calculated using the method of Kaplan-Meier. 
Confidence intervals (CI) for median PFS and median OS 
were constructed using the method of Brookmeyer-Crowley.12
TABLE 1.  Clinicopathologic Characteristics of Advanced 
MPM Patients
N (%)
Median age (yrs) (range) 67.0 (45.8–81.3)
Sex
  Male
45 (76)
  Female
14 (24)
Race
  White
55 (93)
  Black
1 (2)
  Unknown
3 (5)
Histology
  Epithelial
36 (61)
  Biphasic
4 (7)
  Sarcomatous
0 (0)
  NOS
17 (29)
  Not reported
2 (3)
Prior systemic regimens
  1
34 (58)
  2
25 (42)
Zubrod performance status
  0
13 (22)
  1
46 (78)
No. of metastatic sites
  None
5 (8)
  Single
23 (39)
  Multiple
31 (53)
Weight loss past 6 months
  <5%
47 (80)
  5–<10%
6 (10)
  10–20%
6 (10)
  >20%
0 (0)
NOS, not otherwise specified.
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RESULTS
Patients
The protocol was activated on December 1, 2008 and 
completed accrual on September 15, 2010. Sixty-one patients 
were enrolled. One patient was ineligible due to having an ele-
vated baseline international normalized ratio (>1.5). Another 
patient refused treatment and is not evaluable for any of the 
study endpoints. The majority of the 59 evaluable patients were 
male, Caucasian, had epithelioid histology and multiple sites of 
metastases, with weight loss less than 5%, and performance sta-
tus of 1. An almost equal number of patients had received either 
one or two prior chemotherapy regimens (Table 1).
Treatment
The median number of treatment cycles administered 
was 2 (range: 1–12), with 25% of patients receiving at least 
4 cycles. During the first two cycles, 50% of the patients 
received at least 88% of the planned dose, with 18 patients 
(31%) receiving 100%.
Response and Survival
Forty-five patients had measurable disease per RECIST 
1.1. There was only one confirmed partial response (ORR = 2%, 
95% CI: 0–12%) that lasted 7 months. Pleural thickness measure-
ments were not performed so this patient could not be assessed 
for response by the modified RECIST criteria. An additional 24 
of these 45 (53%) patients had stable disease by RECIST 1.1 
for a disease control rate of 55% (95% CI: 40–70%). Of the 36 
patients evaluable for response by the modified RECIST criteria, 
there were no responders and 20 patients had stable disease for 
a disease control rate of 56% (95% CI: 38–72%). The 4-month 
PFS rate was 29% (95% CI: 17–41%) by RECIST 1.1 and 27% 
(95% CI: 16–39%) by modified RECIST. A one-sided test of the 
null hypothesis of a 4-month PFS of 30% has a p-value of 0.59. 
The median PFS was 2.8 months (95% CI: 1.8–3.4 months) by 
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FIGURE 1. A, Progression-free survival 
by RECIST 1.1. B, Progression-free 
survival by modified RECIST for pleural 
tumors.
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both RECIST 1.1 (Figure 1A) and modified RECIST (95% CI: 
1.8–3.5 months) (Figure 1A). The median OS was 6.3 months 
(95% CI: 4.8–8.0 months) (Figure 2). There was no difference in 
median PFS among patients who had received one or two prior 
regimens, p = 0.74. The median OS of patients with epitheli-
oid histology (6 months; 95% CI: 4.7–9.1) was not significantly 
different than in patients with nonepithelioid histologies (7.6 
months; 95% CI: 3.4–8.1; p = 0.47).
Adverse Events
One death due to dyspnea was deemed possibly related 
to the study drug by the treating investigator. Two other 
patients experienced grade 4 adverse events (dyspnea and 
lung infection, respectively). Eleven patients discontinued 
treatment early because of adverse events. The three most 
common adverse events were fatigue (59%), hypertriglycer-
idemia (44%), and anemia (42%). The three most common 
grade 3–5 adverse events were fatigue (10%), anemia (7%), 
and lung infection (7%) (Table 2).
DISCUSSION
In this phase II study in patient with advanced MPM, who 
failed at least one platinum-containing regimen. We reported a 
4-month PFS rate of 29% with single-agent everolimus which 
is less than the prespecified 50% needed to recommend single-
agent everolimus for further investigations in MPM. The ORR 
was 2% with everolimus and the median OS was 6.3 months 
for all the evaluable patients. The ORR, the 4-month PFS rate, 
and the media PFS\not different using RECIST 1.1 or modified 
RECIST criteria. The 4-month PFS rate of this trial was less 
than the target goal of 50% expected from first line treatment 
for advanced MPM as estimated by the European Organization 
for Research and Treatment of Cancer14 indicating single-agent 
mTOR inhibition lacks sufficient clinical activity in advanced 
MPM to warrant further study.
Inactivation of the tumor suppressor gene (Merlin/NF2) 
is found in up to 40% of advanced mesothelioma13 and can 
lead to the activation of the mTOR pathway and may serve 
as a sentivitiy biomarker to everolimus.14 We have not inves-
tigated the prevalence of inactivations of Merlin/NF2 in our 
patients’ sample but another trial (NCT01024946) with evero-
limus in advanced mesothelioma with Merlin/NF2 loss as 
a sensitivity biomarker has been completed and results are 
pending. Alternatively, combination strategy inhibiting both 
PI3K and mTOR may prove to be more successful in treating 
mesothelioma.15
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FIGURE 2.  Overall survival of the 
entire advanced MPM population.
TABLE 2.  Number of Patients with Treatment-Related 
Adverse Events
All (>15%) ≥Grade3
Fatigue 35 59.3% 6 10.2%
Hypertriglyceridemia 26 44.1% 2 3.4%
Hemoglobin 25 42.4% 4 6.8%
Mucositis, clinical: oral cavity 20 33.9% 2 3.4%
Anorexia 19 32.2% 1 1.7%
Nausea 19 32.2% 0 0%
Cholesterol 17 28.8% 0 0%
Hyperglycemia 17 28.8% 3 5.1%
Diarrhea 15 25.4% 1 1.7%
Platelets 15 25.4% 0 0%
Weight loss 13 22.0% 0 0%
Rash 11 18.6% 1 1.7%
Dyspnea 10 16.9% 3 5.1%
Leukocytes 10 16.9% 0 0%
Mucositis, function: oral cavity 10 16.9% 1 1.7%
Creatinine 9 15.3% 0 0%
Dehydration 2 3.4%
Lung Infection 4 6.8%
Lymphopenia 2 3.4%
Muscle weakness: whole body 2 3.4%
Pneumonitis 2 3.4%
International normalized ratio 1 1.7%
Left ventricular systolic dysfunction 1 1.7%
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